Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

2011

 
07.11.2011
Antitope, Ltd., Announces Antibody Research Agreement with Therapure Biopharma, Inc.
Cambridge UK, 7th November 2011- Antitope Ltd., UK ("Antitope") today announced a research agreement with Therapure Biopharma Inc., Canada ("Therapure") for the generation of therapeutic monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite...
31.10.2011
Antitope Announces Initiation of Antibody Humanization in Collaboration with Kolltan Pharmaceuticals
Cambridge UK, 31st October 2011 - Antitope Ltd., UK ("Antitope") today announced a research agreement with Kolltan Pharmaceuticals, Inc. ("Kolltan") for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its...
19.10.2011
EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
--Consortium Will Receive Six Million Euros from Seventh Framework Programme-- Freising, Germany, October 19th, 2011—The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical...
27.07.2011
Antitope Ltd. Announces Research Cooperation with the University of North Carolina at Chapel Hill
Cambridge UK, 27th July 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with the University of North Carolina at Chapel Hill, NC, USA (“UNC”) for the generation of monoclonal therapeutic antibodies for the treatment of cancer. During...
14.06.2011
Antitope Announces Humanization Research Agreement with IMMIH, University of Cologne
Cambridge UK, 14th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research agreement with the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany (“IMMIH“) for the generation of monoclonal therapeutic antibodies...
06.06.2011
Antitope Announces Humanization Research Agreement with NasVax
Cambridge UK, 7th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with NasVax Ltd., Israel (“NasVax“) for the generation of monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. During the...
25.05.2011
Meet Antitope at BIO International Convention 2011 (Washington DC, USA, 27th – 30th June)
Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in the assessment and removal of immunogenicity from protein therapeutics. Meetings can be arranged...
13.04.2011
Cellmid Signs Antibody Humanisation Collaboration with Antitope
SYDNEY, 13 April 2011: Cellmid Limited (ASX: CDY) has signed a collaboration agreement with Antitope Ltd (Cambridge, UK) for the humanisation of its lead therapeutic monoclonal antibody candidate. The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine...